A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome

Wu, Peggy; Kim, Youn H.; Lavori, Phillip W.; Hoppe, Richard T.; Stockerl-Goldstein, Keith

doi:10.1016/j.bbmt.2009.04.017

Cited by 103 publications

(69 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The authors reported a superior outcome in SS patients without large-cell transformation [49]. Further studies, mostly conducted with a younger and thus not representative patient selection, found comparable results with relapse being the most common reason for transplantation failure [50,51]. All studies demonstrated superior survival rates compared to the expected OS and confirmed the effectiveness of RIC regimens, allowing alloSCT in older patients.…”

Section: Allogeneic Stem Cell Transplantationsupporting

confidence: 55%

Innovative Treatment Concepts for Cutaneous T-Cell Lymphoma Based on Microenvironment Modulation

et al. 2017

View full text Add to dashboard Cite

Cutaneous T-cell lymphomas (CTCL) are a rare and biologically heterogeneous malignant entity comprising mycosis fungoides and Sézary syndrome as the most common subtypes. The current treatment outcome is characterized by high rates of relapse, but survival is usually not significantly shortened in low-stage disease. This is different in tumor-stage disease or aggressive CTCL subtypes where survival is significantly reduced. Recent advances have been made on several levels of tumor biology: Whole genome sequencing has resulted in novel strategies of NF-κB or JAK inhibition, ongoing translational research has revealed new targets like CD30 or CCR4, and, finally, research focusing on impaired immunosurveillance has gained more importance. Based on the growing knowledge about the functional roles of the tumor microenvironment and non-malignant infiltrating cells, current research aims to develop novel CTCL treatment strategies. This review focuses on the mounting evidence for efficiently targeting tumor-infiltrating immune cells and thereby modulating the tumor microenvironment and restoring immunosurveillance.

show abstract

Section: Allogeneic Stem Cell Transplantationsupporting

confidence: 55%

Innovative Treatment Concepts for Cutaneous T-Cell Lymphoma Based on Microenvironment Modulation

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In contrast, the durable remissions observed following allogeneic transplantation may be explained by the graft versus lymphoma immune response [365,366]. A retrospective analysis of 60 patients with advanced-stage MF/SS who underwent allogeneic stem cell transplantation was recently reported [367].…”

Section: High-dose Chemotherapy and Hematopoietic Stem Cell Transplanmentioning

confidence: 99%

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Wilcox

2011

American J Hematol

View full text Add to dashboard Cite

Disease overview: Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell lymphoproliferative disorders involving the skin, the majority of which may be classified as Mycosis fungoides (MF) or Sézary syndrome (SS).Diagnosis: The diagnosis of MF or SS requires the integration of clinical and histopathologic data.Risk‐adapted therapy: Tumor, node, metastasis, and blood (TNMB) staging remains the most important prognostic factor in MF/SS and forms the basis for a “risk‐adapted,” multidisciplinary approach to treatment. For patients with disease limited to the skin, expectant management or skin‐directed therapies is preferred, as both disease‐specific and overall survival for these patients is favorable. In contrast, patients with advanced‐stage disease with significant nodal, visceral, or blood involvement are generally approached with biologic‐response modifiers, denileukin diftitox, and histone deacetylase inhibitors before escalating therapy to include systemic, single‐agent chemotherapy. Multiagent chemotherapy may be used for those patients with extensive visceral involvement requiring rapid disease control. In highly‐selected patients with disease refractory to standard treatments, allogeneic stem‐cell transplantation may be considered. Am. J. Hematol., 2011. © 2011 Wiley‐Liss, Inc.

show abstract

“…Die Autoren berichten von einem besseren Verlauf bei SS-Patienten ohne großzellige Transformation [49]. Auch weitere Studien gelangten zu vergleichbaren Ergebnissen und identifizierten die Rezidivierung als häufigste Form des Transplantatversagens, allerdings wurden sie meist mit einer jüngeren und daher nicht repräsentativen Patientenauswahl durchgeführt [50,51]. Alle Studien ergaben im Vergleich zum erwartbaren OS verbesserte Überlebensraten und bestätigten die Wirksamkeit der RIC-Therapieschemata und die Zulässigkeit der alloSCT auch bei älteren Patienten.…”

Section: Neue Behandlungsansätzeunclassified

Innovative Behandlungskonzepte mit Modulation der Mikroumgebung beim kutanen T-Zell-Lymphom

et al. 2019

View full text Add to dashboard Cite

Kutane T-Zell-Lymphome (CTCL) sinde seltene und biologisch heterogene maligne Erkrankungen; die häufigsten Unterarten sind die Mycosis fungoides und das Sézary-Syndrom. Nach den derzeitigen Therapien ist der Verlauf durch hohe Rezidivraten geprägt, das Überleben ist jedoch in niedrigen Tumorstadien in der Regel nicht signifikant verkürzt. Anders ist dies in höheren Tumorstadien bzw. aggressiveren Subtypen des CTCL; hier ist die Überlebenszeit signifikant reduziert. In jüngster Zeit sind bei verschiedenen Aspekten der Tumorbiologie Fortschritte erzielt worden: Die Genomsequenzierung hat neue Strategien der NF-κB- oder JAK-Inhibition hervorgebracht, in der Translationsforschung wurden neue Zielmoleküle wie CD30 oder CCR4 identifiziert, und nicht zuletzt hat die Forschung zur Beeinträchtigung der Immunüberwachung an Bedeutung gewonnen. Auf der Grundlage der zunehmenden Kenntnis der funktionellen Rollen der Tumormikroumgebung und nichtmaligner infiltrierender Zellen zielt die Forschung gegenwärtig darauf ab, neuartige Behandlungsstrategien bei CTCL zu entwickeln. Im Mittelpunkt dieser Übersichtsarbeit steht die wachsende Evidenz für ein wirksames Targeting tumorinfiltrierender Immunzellen und die dadurch erreichte Modulation der Tumormikroumgebung und Wiederherstellung der Immunüberwachung.

show abstract

A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome

Cited by 103 publications

References 36 publications

Innovative Treatment Concepts for Cutaneous T-Cell Lymphoma Based on Microenvironment Modulation

Innovative Treatment Concepts for Cutaneous T-Cell Lymphoma Based on Microenvironment Modulation

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Innovative Behandlungskonzepte mit Modulation der Mikroumgebung beim kutanen T-Zell-Lymphom

Contact Info

Product

Resources

About